Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single-Dose Phase 1 Study
{{output}}
This Phase 1 study investigated the pharmacokinetics and safety of a single dose of the FDA-approved doxecitine and doxribtimine (266.6 mg/kg; 133.3 mg/kg of deoxycytidine [dC] and deoxythymidine [dT]) in participants with severe (n = 8) or moderate (n = 8) re... ...
